Confirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").[1]
Johnson & Johnson reported second-quarter sales of $25.3 billion, up 6.6%, and adjusted EPS of $2.90, and raised its 2026 outlook to about $101.1 billion in sales and $11.68 adjusted EPS at the midpoint.
Johnson & Johnson reported second-quarter 2026 sales of $25.31 billion, up 6.6% reported, 5.6% operationally and 5.7% on an adjusted operational basis; U.S. sales rose 7.3% to $14.5 billion and international sales 5.7% to $10.8 billion[1].
Net earnings were $5.53 billion, or $2.27 a share; adjusted EPS rose 4.7% to $2.90, and free cash flow for the half was about $8.7 billion[1].
Innovative Medicine sales grew 7.8% to $16.38 billion on Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Tremfya, Spravato and Caplyta, despite a Stelara headwind of about 760 basis points; MedTech grew 4.5% to $8.93 billion[1][6].
J&J raised its 2026 guidance to reported sales of $100.8-101.4 billion (midpoint $101.1 billion, up 7.3%) and adjusted EPS of $11.60-11.75 (midpoint $11.68, up $0.13)[1].
CEO Joaquin Duato said J&J is on track to pass $100 billion in annual revenue for the first time in its 140-year history[1].
Sales beat the roughly $25.05 billion analysts expected and adjusted EPS the $2.85 consensus; Tremfya sales jumped 72.5% to $2 billion, Darzalex reached $4.2 billion, and Abiomed heart-pump sales fell 2% after a U.K. study questioned Impella use[2][5].
On the call the CFO said J&J would share more on strategy, growth catalysts and a longer-term outlook at its enterprise business review on 8 December[4].
Two weeks later, on 29 July, J&J filed updated 2026 guidance to absorb the Firefly Bio acquisition and the Sail Biomedicines collaboration[3].
Confirmed by J&J's release dated "New Brunswick, N.J. (July 15, 2026)", which says it "will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time" (12:30 UTC; the edited transcript is stamped "JULY 15, 2026 / 12:30PM GMT").
MarketBeat: "Johnson & Johnson issued Q2 2026 earnings on July 15, 2026, reporting an EPS of $2.90, which beat analysts' consensus estimates of $2.84"; revenue $25.31 billion against $25.06 billion. An aggregator, so kept low.
J&J's investor note says that on 29 July it published an 8-K updating FY 2026 guidance for the Firefly Bio and Sail Biomedicines deals, the follow-up to the guidance raised on 15 July.[1]
J&J's own posted transcript of the 15 July call ("JULY 15, 2026 / 12:30PM GMT"): the CFO says results "enabled us to confidently raise our" outlook and points to the enterprise business review on 8 December.[1]
CNBC reports on 15 July that J&J beat estimates with $25.31 billion in sales against about $25.05 billion expected and $2.90 adjusted EPS against $2.85, and raised its full-year forecast.
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson·…
予定確度 73%20 日後Scheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]
Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.
1200, East Market Street, East End, Goodyear Heights, Akron, Summit County, Ohio, 44305, United StatesBabcock & Wilcox·…
推定確度 69%47 日後Estimated, not announced: B&W's events page lists no Q3 2026 call yet (the latest is "Aug 10, 2026 5:00 PM ET Babcock[1][3][4][5] & Wilcox Q2 2026 Earnings Conference Call"); every call since August 2023 has been at 5 p.m. ET, all three 2026 calls fell on Mondays (16 March, 11 May, 10 August) and Q3 2025's was "Monday, November 10, 2025 at 5 p.m. ET", so the second Monday of November, 9 November 2026 at 5 p.m. EST (22:00 UTC); Nasdaq's[2] Zacks algorithm instead says "estimated to report earnings on 11/03/2026", and the release itself may come earlier, "prior to" the call.
B&W's third-quarter 2026 report and its 5 p.m. ET call, estimated for Monday 9 November from its pattern of Monday-evening calls; the company has not announced the date yet. The quarter will be measured against its raised $80-105 million 2026 adjusted EBITDA target.
予定確度 85%76 日後J&J set the date itself: CFO Joseph Wolk said on the 15 July Q2 call "We look forward to sharing more on strategy, growth catalysts and a longer-term outlook at our Enterprise business review on December 8", and the source[1] reports he "expects to present stronger growth expectations at its Dec. 8 investor day"; no time or venue has been announced, so the pin sits at J&J's headquarters as an all-day date.
Johnson & Johnson holds its first enterprise business review since December 2023, where CFO Joseph Wolk says it will set out growth above its 5% to 7% long-term target, with a clear line of sight to double digits by the end of the decade.
確定確度 86%69 日前TSMC's[1][2] release, datelined "HSINCHU, Taiwan, R.O.C., Jul. 16, 2026", says TSMC "today announced" its second-quarter results, and the call transcript TSMC posts gives "EVENT DATE/TIME: JULY 16, 2026 / 6:00AM GMT" (2 p.m. Taiwan time, as the FTNN report of TSMC's schedule says: "16日下午2時").
TSMC reported second-quarter revenue of US$40.20 billion, up 33.7% from a year earlier, a 67.7% gross margin and record net income of NT$706.56 billion, guided Q3 revenue to US$44.6-45.8 billion and raised its 2026 capital budget to US$60-64 billion.
確定確度 86%69 日前The release, datelined "ABBOTT[5] PARK, Ill., July 16, 2026", says "Abbott will live-webcast its second-quarter earnings conference call ... at 8 a.m. Central time today", so the pin is 8 a.m. CDT (13:00 UTC) on 16 July 2026.
Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
National Bureau of Economic Research, 1050 Massachusetts Ave, Cambridge, MA
推定確度 74%1.3 年後The market asks only whether the two negative quarters fall anywhere between Q4 2026 and Q4 2027, so there is no single day to hang it on; by the convention for a year-only date the pin takes the last day of 2027. Kalshi[1][3] does not expire it until January 31, 2028, when the advance estimate for Q4 2027 is due. The 25% is the chance on Kalshi’s trade panel, which sits beside a 24¢ Yes price.
Kalshi
Polymarket
Kalshi’s recession market for 2027 prices the chance of two consecutive quarters of negative GDP growth between Q4 2026 and Q4 2027, on the Bureau of Economic Analysis’s advance estimates — despite the KXRECSSNBER ticker, no NBER call is involved. On 20 September 2026 it sat at 25%, its 2026 contract at 6%, and Polymarket’s cumulative "recession by end of 2027" book, which also counts an NBER announcement, was higher still at 34.5%.
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson·…
確定確度 87%56 日前"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
予定確度 80%22 日後TSMC's[1][2][3] own teleconference notice reads "TSMC Third Quarter 2026 Earnings Conference Call ... Thursday, October 15, 2026, 02:00 - 03:30 a.m. Eastern Time / 14:00 - 15:30 p.m. Taiwan Time", so 06:00-07:30 UTC; the notice names no venue yet, so the pin sits at TSMC's headquarters.
TSMC reports third-quarter 2026 results and gives its fourth-quarter outlook at its earnings conference on Thursday 15 October at 2 p.m. Taiwan time, against its own guidance of US$44.6-45.8 billion in revenue and a 65-67% gross margin.
1200, East Market Street, East End, Goodyear Heights, Akron, Summit County, Ohio, 44305, United StatesBabcock & Wilcox·…
確定確度 84%44 日前Stated as firm: the release is datelined "(AKRON, Ohio – August 10, 2026)" with no clock time, and the Form 8-K furnishing it (Item 2.02) shows "Accepted 2026-08-10 16:25:32" (ET) on SEC[4][5] EDGAR, so the pin is timed to 4:25 p.m. ET (20:25 UTC), just before the "Monday, August 10, 2026 at 5 p.m. ET" call.
Revenue rose 130% to $319.7 million, $100.7 million of it from the Base Electron data-centre power project, and B&W swung to a $14.3 million net profit. It raised the top of its 2026 adjusted EBITDA target range to $105 million.
確定確度 82%58 日前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
CityPlace 8 - Hewlett Packard Enterprise, East Mossy Oaks Road, Spring, Texas 77373, United StatesHewlett Packard Enterprise·…
推定確度 72%71 日後HPE[4][6] has not named the date yet (it announced the Q3 call three weeks ahead: "Wednesday, September 2 at 3:30 p.m. CT (4:30 p.m. ET)"); its FY25 Q4 call was "Thursday, December 04, 2025, 05:00 PM Eastern", and MarketBeat[2] says HPE "has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 3rd, 2026" after market close, with Zacks[3] listing 12/03/2026 as "an estimated date". So Thursday 3 December 2026 at 4:30 p.m. ET (21:30 UTC), the time of HPE's latest call, is estimated; its Q4 calls in 2024 and 2025 started at 5:00 p.m. ET.
HPE is expected to report fiscal Q4 and full-year 2026 results after the close, most likely on Thursday 3 December, having guided to $13.9-14.8 billion of quarterly revenue and $1.20-1.30 of non-GAAP EPS; HPE has not yet announced the date.
Johnson & Johnson…
予定確度 73%20 日後Scheduled by J&J's 31 August release: it "will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results" and "The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call"; 8:30 a.m. EDT is 12:30 UTC.[1]Johnson & Johnson releases its third-quarter 2026 results at about 6:45 a.m. Eastern on Tuesday 13 October and reviews them on an 8:30 a.m. investor call hosted by CEO Joaquin Duato and CFO Joseph Wolk.0.83
